How much does Medicaid spend on GLP-1 drugs in each state?
How much does Medicaid spend on GLP-1 drugs in each state?
Pharmacies were reimbursed at least $12.05 billion for GLP-1 drugs paid through Medicaid nationwide in 2025, across at least 11,261,770 prescriptions, according to CMS’s State Drug Utilization Data. That is the total amount reimbursed, federal and state shares together, before the rebates manufacturers pay states. CMS suppressed 81 rows of 513, so these figures are floors. The largest published state amounts in 2025 were California (at least $3.46 billion), Pennsylvania (at least $951.4 million), New York (at least $941.2 million), Michigan (at least $681.1 million) and North Carolina (at least $590.0 million). States with suppressed rows show only a floor and cannot be ranked against the others.
Every state, 2025
Sorted by total amount reimbursed. Each state links to its page, with every year from 2020 and each quarter.
| Alabama | at least $72,334,685 | at least 71,831 | 57 of 171 |
| Alaska | at least $22,152,586 | at least 23,249 | 102 of 202 |
| Arizona | at least $98,252,621 | at least 93,645 | 76 of 215 |
| Arkansas | at least $18,871,001 | at least 24,039 | 111 of 279 |
| California | at least $3,462,543,976 | at least 3,090,452 | 50 of 319 |
| Colorado | at least $127,199,098 | at least 123,012 | 69 of 284 |
| Connecticut | at least $202,814,053 | at least 174,553 | 21 of 141 |
| Delaware | at least $21,354,918 | at least 55,674 | 104 of 218 |
| District of Columbia | at least $28,122,591 | at least 27,754 | 115 of 265 |
| Florida | at least $128,079,710 | at least 133,482 | 85 of 252 |
| Georgia | at least $52,526,193 | at least 59,456 | 76 of 283 |
| Hawaii | at least $33,872,236 | at least 30,478 | 49 of 144 |
| Idaho | at least $46,072,822 | at least 45,954 | 42 of 156 |
| Illinois | at least $305,552,662 | at least 288,522 | 65 of 287 |
| Indiana | at least $204,764,005 | at least 190,162 | 82 of 297 |
| Iowa | at least $87,363,112 | at least 88,518 | 83 of 227 |
| Kansas | at least $53,573,102 | at least 50,903 | 36 of 161 |
| Kentucky | at least $238,314,570 | at least 274,538 | 97 of 292 |
| Louisiana | at least $230,946,267 | at least 230,359 | 63 of 229 |
| Maine | at least $40,616,132 | at least 41,655 | 41 of 162 |
| Maryland | at least $142,812,988 | at least 148,648 | 119 of 308 |
| Massachusetts | at least $404,519,821 | at least 399,030 | 98 of 345 |
| Michigan | at least $681,063,451 | at least 608,028 | 102 of 366 |
| Minnesota | at least $255,696,545 | at least 230,594 | 79 of 337 |
| Mississippi | at least $70,718,721 | at least 61,646 | 115 of 285 |
| Missouri | at least $284,863,196 | at least 285,105 | 47 of 165 |
| Montana | at least $22,195,107 | at least 22,719 | 47 of 139 |
| Nebraska | at least $36,117,422 | at least 37,335 | 48 of 144 |
| Nevada | at least $81,868,395 | at least 70,939 | 84 of 279 |
| New Hampshire | at least $37,487,064 | at least 34,652 | 67 of 190 |
| New Jersey | at least $151,445,199 | at least 165,667 | 135 of 289 |
| New Mexico | at least $64,499,377 | at least 64,832 | 113 of 255 |
| New York | at least $941,187,086 | at least 816,616 | 67 of 245 |
| North Carolina | at least $589,996,654 | at least 484,712 | 94 of 338 |
| North Dakota | at least $3,605,150 | at least 5,852 | 57 of 100 |
| Ohio | at least $406,954,834 | at least 425,347 | 115 of 357 |
| Oklahoma | at least $83,573,455 | at least 82,365 | 66 of 264 |
| Oregon | at least $67,351,293 | at least 72,793 | 106 of 290 |
| Pennsylvania | at least $951,405,819 | at least 844,001 | 107 of 366 |
| Puerto Rico | at least $51,822,634 | at least 48,732 | 37 of 148 |
| Rhode Island | at least $48,888,755 | at least 46,691 | 81 of 250 |
| South Carolina | at least $64,945,523 | at least 65,093 | 105 of 279 |
| South Dakota | at least $15,709,847 | at least 15,602 | 40 of 113 |
| Tennessee | at least $144,104,065 | at least 136,023 | 45 of 189 |
| Texas | at least $179,016,062 | at least 172,353 | 114 of 244 |
| Utah | at least $28,648,950 | at least 28,007 | 97 of 247 |
| Vermont | at least $18,537,316 | at least 17,163 | 38 of 133 |
| Virginia | at least $230,109,559 | at least 227,621 | 123 of 329 |
| Washington | at least $82,653,211 | at least 111,202 | 98 of 281 |
| West Virginia | at least $91,584,548 | at least 94,999 | 53 of 149 |
| Wisconsin | at least $327,847,844 | at least 302,672 | 18 of 168 |
| Wyoming | at least $2,244,963 | at least 2,315 | 76 of 140 |
A state marked “at least” or “Suppressed” has rows CMS withheld, so its full amount is unknown and it cannot be ranked against other states; its place in this order reflects only the rows CMS published.
Nationwide, by year and ingredient
| 2020 | at least $283,898,491 | No data | $567,508,684 | at least $596,408,518 | at least $193,861,115 | at least $671,511 | $7,761,540 | $5,421,897 | at least $1,655,531,756 |
| 2021 | at least $554,820,690 | No data | $680,639,494 | at least $1,188,068,204 | at least $134,241,933 | at least $1,080,158 | $9,594,531 | $4,796,567 | at least $2,573,241,576 |
| 2022 | at least $1,149,248,802 | at least $34,060,250 | $722,777,322 | $2,153,391,817 | at least $98,166,895 | at least $359,908 | $12,192,603 | $4,138,825 | at least $4,174,336,421 |
| 2023 | at least $2,911,348,586 | at least $439,944,750 | $722,050,605 | $2,839,397,030 | at least $82,702,773 | at least $11,027 | $9,422,199 | $3,295,077 | at least $7,008,172,046 |
| 2024 | at least $5,107,538,873 | at least $1,205,743,835 | $294,458,438 | $2,163,300,920 | at least $66,016,586 | No data | $6,859,607 | $2,280,203 | at least $8,846,198,462 |
| 2025 | at least $6,613,338,249 | at least $3,323,545,465 | $145,922,324 | $1,948,292,919 | at least $15,363,655 | No data | $4,455,588 | $1,460,353 | at least $12,052,378,553 |
| 2026 (Q1) | at least $1,251,443,577 | at least $911,460,172 | at least $24,183,285 | $391,170,412 | at least $137,347 | No data | $762,625 | $275,378 | at least $2,579,432,797 |
The amounts are CMS’s “Total Amount Reimbursed” field. CMS’s data dictionary for State Drug Utilization Data says of it:
“This total is not reduced or affected by Medicaid rebates paid to the state. This amount represents both the Federal and State Reimbursement and is inclusive of dispensing fees.”
Its prescription count is “The number of prescriptions reimbursed (by the Medicaid Program ONLY) to pharmacists for the (11-digit NDC) drug for the period covered.”
CMS suppresses some rows (its “Suppression Used” field is true and the counts and amounts are left blank). Here a suppressed row is never counted as zero: a figure that includes suppressed rows is shown as “at least” the sum of the rows CMS did publish, and a figure where every row is suppressed is shown as “Suppressed.” The “Rows suppressed” column gives the count. Where many rows are suppressed, the published sum can be well below the full amount, so floors for different states are not directly comparable.
State totals reflect how many people each program covers and which drugs it pays for; this page does not compare state coverage rules. Fee-for-service and managed care rows are added together.
Common questions
How much did Texas Medicaid spend on GLP-1 drugs in 2025?
Pharmacies were reimbursed at least $179.0 million for GLP-1 drugs paid through Texas Medicaid in 2025, across at least 172,353 prescriptions, according to CMS’s State Drug Utilization Data. That is the total amount reimbursed, federal and state shares together, before the rebates manufacturers pay states. CMS suppressed 114 rows of 244, so these figures are floors.
How much did California Medicaid spend on GLP-1 drugs in 2025?
Pharmacies were reimbursed at least $3.46 billion for GLP-1 drugs paid through California Medicaid in 2025, across at least 3,090,452 prescriptions, according to CMS’s State Drug Utilization Data. That is the total amount reimbursed, federal and state shares together, before the rebates manufacturers pay states. CMS suppressed 50 rows of 319, so these figures are floors.
Why are some state figures marked “at least” or “Suppressed”?
CMS suppresses some rows and leaves their amounts blank. This index never counts a suppressed row as zero: totals that include one are floors, and totals with only suppressed rows are shown as suppressed.
Medicare figures: Medicare and Medicaid spending on GLP-1 drugs.
Sources
- CMS Medicare Part B Spending by Drug (data.cms.gov)
- CMS Medicaid State Drug Utilization Data (Medicaid.gov)
- State Drug Utilization Data 2020 (data.medicaid.gov)
- State Drug Utilization Data 2021 (data.medicaid.gov)
- State Drug Utilization Data 2022 (data.medicaid.gov)
- State Drug Utilization Data 2023 (data.medicaid.gov)
- State Drug Utilization Data 2024 (data.medicaid.gov)
- State Drug Utilization Data 2025 (data.medicaid.gov)
- State Drug Utilization Data 2026 (data.medicaid.gov)
Records last pulled Nov 15, 2026. Every entry links to the original public record.